Project Grant R01CA298320
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $643K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- Federal Project Grant Award Summary The Medical University of South Carolina received a $153,768 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 10, 2025, through July 31, 2028. This award supports research training and investigator development focused on elucidating the role of peroxisome biogenesis in enhancing anti-tumor T cell metabolic fitness and immune function. The grant funds a research initiative...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $616,624 to The Medical University of South Carolina under the Cancer Biology Research program (CFDA 93.396) on May 18, 2026, for research titled "Exploiting Primed Inflammatory Signaling to Target SETD2 Deficient Renal Tumors." The award funds fundamental cancer research investigating the mechanisms by which loss of SETD2 (a histone methyltransferase) in renal cell carcinoma creates...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance research on synthetic lethal (SL) targeting in cancer. This research builds upon the institution's established expertise in identifying and characterizing SL drug targets and seeks to validate and mechanistically characterize the...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $257,472 to The Trustees of Columbia University in the City of New York, Health Sciences Division, effective September 6, 2025, through March 6, 2029, under the Cancer Research Manpower program (CFDA 93.398). This award supports research to dissect the impact of genomic variants on T cell anti-tumor activity, with the objective of enhancing T cell-based immunotherapies for melanoma and leukemia...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $150,784 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of North Carolina at Charlotte, effective September 1, 2025, through August 31, 2027. This two-year research initiative investigates the interplay between Heat Shock Protein 70 (HSP70) chaperone function and cyclin D1/CLN3 cell cycle regulation, with direct implications for cancer therapeutics. The research focuses on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Project Grant Award Summary The National Cancer Institute awarded $452,540 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for a project grant spanning May 1, 2026 through April 30, 2028. The funded research addresses innate and adaptive determinants of cytokine release syndrome (CRS) in chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. The project investigates the molecular mechanisms underlying CRS, a...
- Federal Project Grant Award Summary New York University School of Medicine received a $695,852 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. The project, "Investigating T Cell Circuits in the Lymphatic System During Melanoma Progression," delivers fundamental research services focused on understanding the mechanisms by which stem-like memory (TSL) CD8+ T cells are...